Michael Morales may have punched his ticket to a UFC welterweight title shot last night (Sat., Nov. 15, 2025) at UFC 322 LIVE on ESPN+ pay-per-view (PPV) from inside Madison Square Garden in New York ...

President Donald Trump is facing new scrutiny over the use of a replicated signature on several recent pardons WASHINGTON -- The Justice Department posted pardons ...

Investor Michael Burry sought to clarify certain misconceptions about his latest options bet against Palantir Technologies Inc. (NASDAQ: PLTR), after details of the position were widely misinterpreted ...

Listen to more stories on the Noa app. This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with ...

Recent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1D ...

ESPN’s Rich Eisen, host of the “Rich Eisen Show”, spoke out today about the conflicting quotes that came out of the Atlanta Falcons locker room on Wednesday regarding quarterback Michael Penix Jr. and ...

Reported positive interim data from NGN-401 Phase 1/2 gene therapy trial for Rett syndrome demonstrating multidomain, durable gains, with 35 total developmental milestones/skills acquired across eight ...

Recent data presented at EASD and IPSAD provide further validation for SAB-142 as a novel, potentially best-in-class, disease-modifying, immunotherapeutic approach to redefine treatment of Stage 3 T1D ...

- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors - - On ...

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter ...